{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:09:06Z","timestamp":1792120146988,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["PJT-198035"],"award-info":[{"award-number":["PJT-198035"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["PJT-198035"],"award-info":[{"award-number":["PJT-198035"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77155-2","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:54:05Z","timestamp":1788648845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PRMT7 restricts CD8+ T cells expansion via the NF-\u039aB pathway"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-9331","authenticated-orcid":false,"given":"Nivine","family":"Srour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-3663","authenticated-orcid":false,"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3004-5298","authenticated-orcid":false,"given":"Theodore","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Santinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8279-9446","authenticated-orcid":false,"given":"Anthony","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7833-4228","authenticated-orcid":false,"given":"John","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-9621","authenticated-orcid":false,"given":"Dalia","family":"Barsyte-Lovejoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Lehoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia V.","family":"del Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-4806","authenticated-orcid":false,"given":"St\u00e9phane","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"77155_CR1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41568-023-00565-7","volume":"23","author":"PP Centeno","year":"2023","unstructured":"Centeno, P. P., Pavet, V. & Marais, R. The journey from melanocytes to melanoma. Nat. Rev. Cancer 23, 372\u2013390https:\/\/doi.org\/10.1038\/s41568-023-00565-7 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"77155_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41467-024-45221-2","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 381, 1535\u20131546https:\/\/doi.org\/10.1038\/s41467-024-45221-2 (2019).","journal-title":"N. Engl. J. Med."},{"key":"77155_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45221-2","volume":"15","author":"S Jilani","year":"2024","unstructured":"Jilani, S. et al. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat. Commun. 15, 1244https:\/\/doi.org\/10.1038\/s41467-024-45221-2 (2024).","journal-title":"Nat. Commun."},{"key":"77155_CR4","doi-asserted-by":"publisher","unstructured":"Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer 10 https:\/\/doi.org\/10.1136\/jitc-2022-005755 (2022).","DOI":"10.1136\/jitc-2022-005755"},{"key":"77155_CR5","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1016\/j.molcel.2021.09.011","volume":"81","author":"J Xu","year":"2021","unstructured":"Xu, J. & Richard, S. Cellular pathways influenced by protein arginine methylation: Implications for cancer. Mol. Cell 81, 4357\u20134368 https:\/\/doi.org\/10.1016\/j.molcel.2021.09.011 (2021).","journal-title":"Mol. Cell"},{"key":"77155_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","volume":"33","author":"MT Bedford","year":"2009","unstructured":"Bedford, M. T. & Clarke, S. G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 33, 1\u201313 (2009).","journal-title":"Mol. Cell"},{"key":"77155_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.abb.2019.02.014","volume":"665","author":"K Jain","year":"2019","unstructured":"Jain, K. & Clarke, S. G. PRMT7 as a unique member of the protein arginine methyltransferase family: a review. Arch. Biochem Biophys. 665, 36\u201345 (2019).","journal-title":"Arch. Biochem Biophys."},{"key":"77155_CR8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1091\/mbc.E18-05-0330","volume":"30","author":"N Haghandish","year":"2019","unstructured":"Haghandish, N. et al. PRMT7 methylates eukaryotic translation initiation factor 2\u03b1 and regulates its role in stress granule formation. Mol. Biol. Cell 30, 778\u2013793 (2019).","journal-title":"Mol. Biol. Cell"},{"key":"77155_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110582","volume":"38","author":"N Srour","year":"2022","unstructured":"Srour, N. et al. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell Rep. 38, 110582 https:\/\/doi.org\/10.1016\/j.celrep.2022.110582 (2022).","journal-title":"Cell Rep."},{"key":"77155_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408117121","volume":"121","author":"J Yang","year":"2024","unstructured":"Yang, J. et al. Targeting PRMT7-mediated monomethylation of MAVS enhances antiviral innate immune responses and inhibits RNA virus replication. Proc. Natl. Acad. Sci. USA 121, e2408117121 https:\/\/doi.org\/10.1073\/pnas.2408117121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77155_CR11","doi-asserted-by":"publisher","first-page":"37010","DOI":"10.1074\/jbc.M113.525345","volume":"288","author":"Y Feng","year":"2013","unstructured":"Feng, Y. et al. Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and arginine-rich regions. J. Biol. Chem. 288, 37010\u201337025 (2013).","journal-title":"J. Biol. Chem."},{"key":"77155_CR12","doi-asserted-by":"publisher","unstructured":"Szewczyk, M. M. et al. Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response. Nat. Commun. Bioxiv- https:\/\/doi.org\/10.1101\/503136 (2020).","DOI":"10.1101\/503136"},{"key":"77155_CR13","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1016\/j.molcel.2021.06.004","volume":"81","author":"J Zhu","year":"2021","unstructured":"Zhu, J. et al. Arginine monomethylation by PRMT7 controls MAVS-mediated antiviral innate immunity. Mol. Cell 81, 3171\u20133186 e3178 https:\/\/doi.org\/10.1016\/j.molcel.2021.06.004 (2021).","journal-title":"Mol. Cell"},{"key":"77155_CR14","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.18632\/oncotarget.3072","volume":"6","author":"RM Baldwin","year":"2015","unstructured":"Baldwin, R. M. et al. Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget 6, 3013\u20133032 https:\/\/doi.org\/10.18632\/oncotarget.3072 (2015).","journal-title":"Oncotarget"},{"key":"77155_CR15","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1158\/0008-5472.CAN-14-0800","volume":"74","author":"R Yao","year":"2014","unstructured":"Yao, R. et al. PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer. Cancer Res. 74, 5656\u20135667 https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0800 (2014).","journal-title":"Cancer Res."},{"key":"77155_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cmet.2022.04.004","volume":"34","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell Metab. 34, 818\u2013835 e817 https:\/\/doi.org\/10.1016\/j.cmet.2022.04.004 (2022).","journal-title":"Cell Metab."},{"key":"77155_CR17","doi-asserted-by":"publisher","first-page":"8244","DOI":"10.1021\/acs.jmedchem.4c02978","volume":"68","author":"J Li","year":"2025","unstructured":"Li, J. et al. Development of novel PRMT7 inhibitors for the treatment of prostate cancer. J. Med. Chem. 68, 8244\u20138268 https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02978 (2025).","journal-title":"J. Med. Chem."},{"key":"77155_CR18","doi-asserted-by":"publisher","first-page":"9977","DOI":"10.1021\/acs.jmedchem.0c01111","volume":"63","author":"Y Shen","year":"2020","unstructured":"Shen, Y. et al. Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders. J. Med. Chem. 63, 9977\u20139989 https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01111 (2020).","journal-title":"J. Med. Chem."},{"key":"77155_CR19","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1021\/acs.jmedchem.0c00406","volume":"63","author":"Y Shen","year":"2020","unstructured":"Shen, Y. et al. Discovery of a first-in-class protein arginine methyltransferase 6 (PRMT6) covalent inhibitor. J. Med. Chem. 63, 5477\u20135487 https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00406 (2020).","journal-title":"J. Med. Chem."},{"key":"77155_CR20","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.celrep.2016.01.022","volume":"14","author":"RS Blanc","year":"2016","unstructured":"Blanc, R. S., Vogel, G., Chen, T., Crist, C. & Richard, S. PRMT7 preserves satellite cell regenerative capacity. Cell Rep. 14, 1528\u20131539 (2016).","journal-title":"Cell Rep."},{"key":"77155_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin, M. & Bigley, V. Human dendritic cell subsets: an update. Immunology 154, 3\u201320 https:\/\/doi.org\/10.1111\/imm.12888 (2018).","journal-title":"Immunology"},{"key":"77155_CR22","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1128\/JVI.75.14.6710-6713.2001","volume":"75","author":"S Patterson","year":"2001","unstructured":"Patterson, S., Rae, A., Hockey, N., Gilmour, J. & Gotch, F. Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J. Virol. 75, 6710\u20136713 https:\/\/doi.org\/10.1128\/JVI.75.14.6710-6713.2001 (2001).","journal-title":"J. Virol."},{"key":"77155_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330\u2013336 https:\/\/doi.org\/10.1038\/ni904 (2003).","journal-title":"Nat. Immunol."},{"key":"77155_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","volume":"100","author":"SJ Szabo","year":"2000","unstructured":"Szabo, S. J. et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655\u2013669 (2000).","journal-title":"Cell"},{"key":"77155_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/s0092-8674(00)80240-8","volume":"89","author":"W Zheng","year":"1997","unstructured":"Zheng, W. & Flavell, R. A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89, 587\u2013596 https:\/\/doi.org\/10.1016\/s0092-8674(00)80240-8 (1997).","journal-title":"Cell"},{"key":"77155_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121\u20131133 https:\/\/doi.org\/10.1016\/j.cell.2006.07.035 (2006).","journal-title":"Cell"},{"key":"77155_CR27","doi-asserted-by":"publisher","first-page":"10101","DOI":"10.1073\/pnas.1706978114","volume":"114","author":"K Jain","year":"2017","unstructured":"Jain, K., Jin, C. Y. & Clarke, S. G. Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases. Proc. Natl. Acad. Sci. USA 114, 10101\u201310106 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77155_CR28","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1084\/jem.188.12.2301","volume":"188","author":"HS Azzam","year":"1998","unstructured":"Azzam, H. S. et al. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J. Exp. Med. 188, 2301\u20132311 https:\/\/doi.org\/10.1084\/jem.188.12.2301 (1998).","journal-title":"J. Exp. Med."},{"key":"77155_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4049\/jimmunol.1004145","volume":"187","author":"M Tabbekh","year":"2011","unstructured":"Tabbekh, M. et al. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J. Immunol. 187, 102\u2013109 https:\/\/doi.org\/10.4049\/jimmunol.1004145 (2011).","journal-title":"J. Immunol."},{"key":"77155_CR30","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e20","volume":"20","author":"H Choi","year":"2020","unstructured":"Choi, H., Song, H. & Jung, Y. W. The roles of CCR7 for the homing of memory CD8+ T cells into their survival niches. Immune Netw. 20, e20 https:\/\/doi.org\/10.4110\/in.2020.20.e20 (2020).","journal-title":"Immune Netw."},{"key":"77155_CR31","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.scib.2021.01.004","volume":"66","author":"HH Wei","year":"2021","unstructured":"Wei, H. H. et al. A systematic survey of PRMT interactomes reveals the key roles of arginine methylation in the global control of RNA splicing and translation. Sci. Bull. 66, 1342\u20131357 https:\/\/doi.org\/10.1016\/j.scib.2021.01.004 (2021).","journal-title":"Sci. Bull."},{"key":"77155_CR32","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1349-7006.2006.00285.x","volume":"97","author":"K Umezawa","year":"2006","unstructured":"Umezawa, K. Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci. 97, 990\u2013995 https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00285.x (2006).","journal-title":"Cancer Sci."},{"key":"77155_CR33","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1039\/d2cs00387b","volume":"51","author":"CJ Diehl","year":"2022","unstructured":"Diehl, C. J. & Ciulli, A. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Chem. Soc. Rev. 51, 8216\u20138257 https:\/\/doi.org\/10.1039\/d2cs00387b (2022).","journal-title":"Chem. Soc. Rev."},{"key":"77155_CR34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638\u2013654 https:\/\/doi.org\/10.1038\/s41568-021-00365-x (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"77155_CR35","doi-asserted-by":"publisher","first-page":"27280","DOI":"10.1074\/jbc.271.44.27280","volume":"271","author":"DH Lee","year":"1996","unstructured":"Lee, D. H. & Goldberg, A. L. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J. Biol. Chem. 271, 27280\u201327284 https:\/\/doi.org\/10.1074\/jbc.271.44.27280 (1996).","journal-title":"J. Biol. Chem."},{"key":"77155_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732\u2013736 https:\/\/doi.org\/10.1038\/nature07884 (2009).","journal-title":"Nature"},{"key":"77155_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00262-008-0562-x","volume":"58","author":"JA Wargo","year":"2009","unstructured":"Wargo, J. A. et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58, 383\u2013394 https:\/\/doi.org\/10.1007\/s00262-008-0562-x (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"77155_CR38","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/0008-5472.CAN-24-1875","volume":"85","author":"D Allard","year":"2025","unstructured":"Allard, D. et al. Adenosine uptake through the nucleoside transporter ENT1 suppresses antitumor immunity and T cell pyrimidine synthesis. Cancer Res. 85, 692\u2013703 https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-1875 (2025).","journal-title":"Cancer Res."},{"key":"77155_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44\u201355 https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0945 (2014).","journal-title":"Clin. Cancer Res."},{"key":"77155_CR40","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/pnas.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 108, 7142\u20137147 https:\/\/doi.org\/10.1073\/pnas.1016569108 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77155_CR41","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1158\/1078-0432.CCR-08-0285","volume":"14","author":"O Murillo","year":"2008","unstructured":"Murillo, O. et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin. Cancer Res. 14, 6895\u20136906 https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0285 (2008).","journal-title":"Clin. Cancer Res."},{"key":"77155_CR42","doi-asserted-by":"publisher","unstructured":"Khushalani, N. I. et al. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. J. Immunother. Cancer 12 https:\/\/doi.org\/10.1136\/jitc-2023-007364(2024).","DOI":"10.1136\/jitc-2023-007364"},{"key":"77155_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/ni.2785","volume":"15","author":"S Gerondakis","year":"2014","unstructured":"Gerondakis, S., Fulford, T. S., Messina, N. L. & Grumont, R. J. NF-kappaB control of T cell development. Nat. Immunol. 15, 15\u201325 https:\/\/doi.org\/10.1038\/ni.2785 (2014).","journal-title":"Nat. Immunol."},{"key":"77155_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev.immunol.24.021605.090547","volume":"24","author":"SF Ziegler","year":"2006","unstructured":"Ziegler, S. F. FOXP3: of mice and men. Annu. Rev. Immunol. 24, 209\u2013226 https:\/\/doi.org\/10.1146\/annurev.immunol.24.021605.090547 (2006).","journal-title":"Annu. Rev. Immunol."},{"key":"77155_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-1221-6_1","volume":"825","author":"S Gerstberger","year":"2014","unstructured":"Gerstberger, S., Hafner, M., Ascano, M. & Tuschl, T. Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease. Adv. Exp. Med. Biol. 825, 1\u201355 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"key":"77155_CR46","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.4049\/jimmunol.165.9.5004","volume":"165","author":"T Hettmann","year":"2000","unstructured":"Hettmann, T., Leiden, J. M. & NF-kappa, B. Is required for the positive selection of CD8+ thymocytes. J. Immunol. 165, 5004\u20135010 https:\/\/doi.org\/10.4049\/jimmunol.165.9.5004 (2000).","journal-title":"J. Immunol."},{"key":"77155_CR47","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/(SICI)1521-4141(199909)","volume":"29","author":"AL Mora","year":"1999","unstructured":"Mora, A. L., Chen, D., Boothby, M. & Rubin, D. H. Lineage-specific differences among CD8+ T cells in their dependence of NF-kappa B\/Rel signaling. Eur. J. Immunol. 29, 2968\u20132980, https:\/\/doi.org\/10.1002\/(SICI)1521-4141(199909) (1999).","journal-title":"Eur. J. Immunol."},{"key":"77155_CR48","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1038\/sj.onc.1209939","volume":"25","author":"G Courtois","year":"2006","unstructured":"Courtois, G. & Gilmore, T. D. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25, 6831\u20136843 https:\/\/doi.org\/10.1038\/sj.onc.1209939 (2006).","journal-title":"Oncogene"},{"key":"77155_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/s1074-7613(03)00237-1","volume":"19","author":"M Schmidt-Supprian","year":"2003","unstructured":"Schmidt-Supprian, M. et al. Mature T cells depend on signaling through the IKK complex. Immunity 19, 377\u2013389 https:\/\/doi.org\/10.1016\/s1074-7613(03)00237-1 (2003).","journal-title":"Immunity"},{"key":"77155_CR50","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1074\/jbc.M111.294876","volume":"287","author":"YK Mburu","year":"2012","unstructured":"Mburu, Y. K. et al. Chemokine receptor 7 (CCR7) gene expression is regulated by NF-kappaB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). J. Biol. Chem. 287, 3581\u20133590 https:\/\/doi.org\/10.1074\/jbc.M111.294876 (2012).","journal-title":"J. Biol. Chem."},{"key":"77155_CR51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.immuni.2008.08.010","volume":"29","author":"E Jimi","year":"2008","unstructured":"Jimi, E., Strickland, I., Voll, R. E., Long, M. & Ghosh, S. Differential role of the transcription factor NF-kappaB in selection and survival of CD4+ and CD8+ thymocytes. Immunity 29, 523\u2013537 (2008).","journal-title":"Immunity"},{"key":"77155_CR52","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity 49, 1148\u20131161 e1147 https:\/\/doi.org\/10.1016\/j.immuni.2018.09.024 (2018).","journal-title":"Immunity"},{"key":"77155_CR53","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.trecan.2020.04.003","volume":"6","author":"B Eluard","year":"2020","unstructured":"Eluard, B., Thieblemont, C. & Baud, V. NF-kappaB in the new era of cancer therapy. Trends Cancer 6, 677\u2013687 https:\/\/doi.org\/10.1016\/j.trecan.2020.04.003 (2020).","journal-title":"Trends Cancer"},{"key":"77155_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451245","volume":"54","author":"G Dabbah-Krancher","year":"2024","unstructured":"Dabbah-Krancher, G. et al. A20 intrinsically influences human effector T cell survival and function by regulating both NF-kappaB and JNK signaling. Eur. J. Immunol. 54, e2451245 https:\/\/doi.org\/10.1002\/eji.202451245 (2024).","journal-title":"Eur. J. Immunol."},{"key":"77155_CR55","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00018-022-04154-z","volume":"79","author":"H Yin","year":"2022","unstructured":"Yin, H. et al. A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-kappaB signaling in activated T cells. Cell Mol. Life Sci. 79, 112 https:\/\/doi.org\/10.1007\/s00018-022-04154-z (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"77155_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal Transduct. Target Ther. 2, 17023 https:\/\/doi.org\/10.1038\/sigtrans.2017.23 (2017).","journal-title":"Signal Transduct. Target Ther."},{"key":"77155_CR57","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.4049\/jimmunol.1102429","volume":"189","author":"S Krishna","year":"2012","unstructured":"Krishna, S. et al. Chronic activation of the kinase IKKbeta impairs T cell function and survival. J. Immunol. 189, 1209\u20131219 https:\/\/doi.org\/10.4049\/jimmunol.1102429 (2012).","journal-title":"J. Immunol."},{"key":"77155_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28809-4","volume":"13","author":"G Gunes Gunsel","year":"2022","unstructured":"Gunes Gunsel, G. et al. The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. Nat. Commun. 13, 1303 https:\/\/doi.org\/10.1038\/s41467-022-28809-4 (2022).","journal-title":"Nat. Commun."},{"key":"77155_CR59","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2007.10.009","volume":"131","author":"F Wan","year":"2007","unstructured":"Wan, F. et al. Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell 131, 927\u2013939 https:\/\/doi.org\/10.1016\/j.cell.2007.10.009 (2007).","journal-title":"Cell"},{"key":"77155_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2916","volume":"4","author":"K Fu","year":"2013","unstructured":"Fu, K. et al. Sam68 modulates the promoter specificity of NF-kappaB and mediates expression of CD25 in activated T cells. Nat. Commun. 4, 1909 https:\/\/doi.org\/10.1038\/ncomms2916 (2013).","journal-title":"Nat. Commun."},{"key":"77155_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.emboj.7600500","volume":"24","author":"M Covic","year":"2005","unstructured":"Covic, M. et al. Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression. EMBO J. 24, 85\u201396 (2005).","journal-title":"EMBO J."},{"key":"77155_CR62","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jmb.2008.01.044","volume":"377","author":"PO Hassa","year":"2008","unstructured":"Hassa, P. O., Covic, M., Bedford, M. T. & Hottiger, M. O. Protein arginine methyltransferase 1 coactivates NF-kappaB-dependent gene expression synergistically with CARM1 and PARP1. J. Mol. Biol. 377, 668\u2013678 https:\/\/doi.org\/10.1016\/j.jmb.2008.01.044 (2008).","journal-title":"J. Mol. Biol."},{"key":"77155_CR63","doi-asserted-by":"publisher","first-page":"13516","DOI":"10.1073\/pnas.1311784110","volume":"110","author":"H Wei","year":"2013","unstructured":"Wei, H. et al. PRMT5 dimethylates R30 of the p65 subunit to activate NF-kappaB. Proc. Natl. Acad. Sci. USA 110, 13516\u201313521 https:\/\/doi.org\/10.1073\/pnas.1311784110 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77155_CR64","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.1093\/nar\/gku530","volume":"42","author":"A Di Lorenzo","year":"2014","unstructured":"Di Lorenzo, A., Yang, Y., Macaluso, M. & Bedford, M. T. A gain-of-function mouse model identifies PRMT6 as a NF-kappaB coactivator. Nucleic Acids Res. 42, 8297\u20138309 https:\/\/doi.org\/10.1093\/nar\/gku530 (2014).","journal-title":"Nucleic Acids Res."},{"key":"77155_CR65","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2020.05.004","volume":"37","author":"D Gurusamy","year":"2020","unstructured":"Gurusamy, D. et al. Multi-phenotype CRISPR-Cas9 Screen Identifies p38 kinase as a target for adoptive immunotherapies. Cancer Cell 37, 818\u2013833 e819 https:\/\/doi.org\/10.1016\/j.ccell.2020.05.004 (2020).","journal-title":"Cancer Cell"},{"key":"77155_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp9371","volume":"10","author":"AJ Dimitri","year":"2024","unstructured":"Dimitri, A. J. et al. TET2 regulates early and late transitions in exhausted CD8(+) T cell differentiation and limits CAR T cell function. Sci. Adv. 10, eadp9371 https:\/\/doi.org\/10.1126\/sciadv.adp9371 (2024).","journal-title":"Sci. Adv."},{"key":"77155_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 https:\/\/doi.org\/10.1126\/scitranslmed.abh0272 (2021).","journal-title":"Sci. Transl. Med."},{"key":"77155_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114065","volume":"43","author":"M Zhu","year":"2024","unstructured":"Zhu, M. et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 43, 114065 https:\/\/doi.org\/10.1016\/j.celrep.2024.114065 (2024).","journal-title":"Cell Rep."},{"key":"77155_CR69","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1744-313x.1996.tb00127.x","volume":"23","author":"L Amiot","year":"1996","unstructured":"Amiot, L. et al. Distribution of HLA-G alternative mRNAs including soluble forms in normal lymphocytes and in lymphoid cell-derived leukemia. Eur. J. Immunogenet. 23, 311\u2013320 https:\/\/doi.org\/10.1111\/j.1744-313x.1996.tb00127.x (1996).","journal-title":"Eur. J. Immunogenet."},{"key":"77155_CR70","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216 e1208 https:\/\/doi.org\/10.1016\/j.ccell.2024.05.025 (2024).","journal-title":"Cancer Cell"},{"key":"77155_CR71","doi-asserted-by":"publisher","first-page":"7944","DOI":"10.18632\/oncotarget.3501","volume":"6","author":"E Rao","year":"2015","unstructured":"Rao, E. et al. Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death. Oncotarget 6, 7944\u20137958 https:\/\/doi.org\/10.18632\/oncotarget.3501 (2015).","journal-title":"Oncotarget"},{"key":"77155_CR72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri3198","volume":"12","author":"H Chi","year":"2012","unstructured":"Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325\u2013338 https:\/\/doi.org\/10.1038\/nri3198 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"77155_CR73","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2014.12.030","volume":"42","author":"J Blagih","year":"2015","unstructured":"Blagih, J. et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42, 41\u201354 https:\/\/doi.org\/10.1016\/j.immuni.2014.12.030 (2015).","journal-title":"Immunity"},{"key":"77155_CR74","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cmet.2020.01.006","volume":"31","author":"DG Roy","year":"2020","unstructured":"Roy, D. G. et al. Methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming. Cell Metab. 31, 250\u2013266 e259 https:\/\/doi.org\/10.1016\/j.cmet.2020.01.006 (2020).","journal-title":"Cell Metab."},{"key":"77155_CR75","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1038\/s41596-021-00586-2","volume":"16","author":"RD Sheldon","year":"2021","unstructured":"Sheldon, R. D., Ma, E. H., DeCamp, L. M., Williams, K. S. & Jones, R. G. Interrogating in vivo T cell metabolism in mice using stable isotope labeling metabolomics and rapid cell sorting. Nat. Protoc. 16, 4494\u20134521 https:\/\/doi.org\/10.1038\/s41596-021-00586-2 (2021).","journal-title":"Nat. Protoc."},{"key":"77155_CR76","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj3020","volume":"387","author":"S Ma","year":"2025","unstructured":"Ma, S. et al. Nutrient-driven histone code determines exhausted CD8(+) T cell fates. Science 387, eadj3020 https:\/\/doi.org\/10.1126\/science.adj3020 (2025).","journal-title":"Science"},{"key":"77155_CR77","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41590-025-02185-9","volume":"26","author":"MS Dahabieh","year":"2025","unstructured":"Dahabieh, M. S. et al. The prostacyclin receptor PTGIR is a NRF2-dependent regulator of CD8(+) T cell exhaustion. Nat. Immunol. 26, 1139\u20131151 https:\/\/doi.org\/10.1038\/s41590-025-02185-9 (2025).","journal-title":"Nat. Immunol."},{"key":"77155_CR78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.chom.2012.06.009","volume":"12","author":"SM Belgnaoui","year":"2012","unstructured":"Belgnaoui, S. M. et al. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe 12, 211\u2013222 https:\/\/doi.org\/10.1016\/j.chom.2012.06.009 (2012).","journal-title":"Cell Host Microbe"},{"key":"77155_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115365","volume":"44","author":"D Berry","year":"2025","unstructured":"Berry, D. et al. The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma. Cell Rep. 44, 115365 https:\/\/doi.org\/10.1016\/j.celrep.2025.115365 (2025).","journal-title":"Cell Rep."},{"key":"77155_CR80","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766\u2013D773 (2019).","journal-title":"Nucleic Acids Res."},{"key":"77155_CR81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"77155_CR82","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"77155_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"77155_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06211-1","volume":"7","author":"L Darbelli","year":"2017","unstructured":"Darbelli, L., Choquet, K., Richard, S. & Kleinman, C. L. Transcriptome profiling of mouse brains with QKI-deficient oligodendrocytes reveals major alternative splicing defects including self-splicing. Sci. Rep. 7, 7554 (2017).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77155-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77155-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77155-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:52:44Z","timestamp":1791327164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77155-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77155"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77155-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing financial interest(s): J. J. is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. J.S. is a scientific advisory board member of Coherus Oncology, Domain Therapeutics and Ability Biotherapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10564"}}